Tirzepatide is a dual GIP and GLP-1 receptor agonist. It hits two gut hormone receptors to suppress appetite and slow digestion. It is FDA-approved as Mounjaro and Zepbound.

Retatrutide is a triple agonist that hits GLP-1, GIP, and glucagon receptors. It is still in Phase 3 clinical trials and is not yet FDA-approved.

Tirzepatide vs Retatrutide: Which One Works Better?

Q: Is retatrutide available to use?

No. As of mid-2026, retatrutide is still in clinical trials and is not FDA-approved. It is not available by prescription or through standard channels.

Built by medical professionals, gym rats, and experienced biohackers

Tirzepatide works well and is available now. Retatrutide may work better by targeting a third hormone, but it is not yet approved and most people cannot get it yet.

Tirzepatide or Retatrutide: Which Is Worth Your Attention?

Tirzepatide (Mounjaro, Zepbound) hits two hormone receptors (GLP-1 and GIP) and is FDA-approved for weight loss. Retatrutide hits three receptors (GLP-1, GIP, and glucagon) and is still in late-stage trials. Early data suggests retatrutide may produce more weight loss , but it is not available outside of clinical research.

What Is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates two gut hormone receptors that together slow digestion and reduce appetite.

It is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. The SURMOUNT trials showed average body weight reductions of roughly 20 to 22% over 72 weeks .

What Is Retatrutide?

Retatrutide is a triple agonist. It activates three hormone receptors: GLP-1, GIP, and glucagon.

The glucagon receptor is what makes retatrutide different. Glucagon tells the liver to burn stored energy and raises your metabolic rate. Phase 2 data showed very high weight-loss numbers. Adding glucagon activation on top of GLP-1 and GIP may explain why .

As of mid-2026, retatrutide is in Phase 3 trials and is not FDA-approved .

How Do They Differ?

Feature	Tirzepatide	Retatrutide
Receptor targets	GLP-1 and GIP	GLP-1, GIP, and glucagon
FDA approval	Yes (Mounjaro, Zepbound)	No (still in trials)
Availability	Prescription from a doctor	Clinical trial participants only
Typical dose	Up to 15 mg weekly	4 to 12 mg weekly in trials
Average weight loss seen	Roughly 20 to 22%	Up to 24% in Phase 2
Evidence level	Full FDA approval, large trial data	Phase 2 complete; Phase 3 pending

Mechanism. Tirzepatide targets GLP-1 and GIP. Both slow digestion and signal fullness. Retatrutide adds glucagon receptor activation, which may boost energy use and fat burning beyond what the other two can do alone .

Evidence level. Tirzepatide has the backing of large, completed Phase 3 trials. Retatrutide Phase 2 data looks promising, but Phase 2 trials are smaller and shorter. Phase 3 results will tell a more complete story about real-world effectiveness and side effects.

Availability. This is the biggest practical difference right now. Tirzepatide is available by prescription. Retatrutide is not.

Can You Take Both Together?

No. Both target overlapping GLP-1 and GIP receptors. Combining them would not stack the benefits and could raise the risk of side effects. They should not be used together.

How Do You Track These Weight-Loss Protocols?

Weight-loss drug protocols often involve gradual dose titration over many months. People on structured protocols find it useful to track their dose, weight changes, and side effects in one place. DoseVault is designed for that kind of ongoing log, whether you are on a current drug or following the retatrutide trials closely.

Frequently Asked Questions

What is tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is FDA-approved as Mounjaro and Zepbound and suppresses appetite by mimicking two gut hormones.

What is retatrutide?
Retatrutide is a triple agonist (GLP-1, GIP, glucagon) still in Phase 3 clinical trials and not yet FDA-approved.

Is retatrutide available to use?
No. As of mid-2026, retatrutide is not approved and is only accessible through clinical trials.

Which causes more weight loss, tirzepatide or retatrutide?
Early Phase 2 data suggests retatrutide may produce greater average weight loss , but Phase 3 data is still pending.

Which Do People Pick, and When?

This is general guidance, not personalized medical advice. Discuss your options with a licensed clinician.

Choose tirzepatide if:
- You want an FDA-approved option available now
- Your doctor supports it for your health profile
- You want large-scale trial data behind your choice

Watch retatrutide if:
- You follow the latest weight-loss research
- You are interested in what may be available in the next few years
- You are already getting good results with tirzepatide and want to know what comes next

This page is educational only. It is not medical advice and does not replace consultation with a licensed healthcare provider. Prescription drugs require a doctor's supervision. Do not use these drugs to diagnose, treat, cure, or prevent any condition.

Built by medical professionals, gym rats, and experienced biohackers

Tracking a GLP-1 protocol? DoseVault makes it simple to log your titration schedule, weekly weight, and notes across the full length of your protocol.